

# US Patent & Trademark Office

## Patent Public Search | Text View

---

United States Patent	12390431
Kind Code	B2
Date of Patent	August 19, 2025
Inventor(s)	Somberg; John Charin et al.

---

### Method of escalating sotalol hydrochloride dosing

---

#### Abstract

This disclosure provides a method of safely and rapidly initiating or escalating oral sotalol therapy by administering an intravenous dosage of sotalol followed by oral sotalol twice daily.

---

**Inventors:** Somberg; John Charin (Chicago, IL), Kashfian; Brandon Ira (Chicago, IL), Molnar; Janos (Chicago, IL)

**Applicant:** AltaThera Pharmaceuticals LLC (Chicago, IL)

**Family ID:** 1000008763803

**Assignee:** AltaThera Pharmaceuticals LLC (Chicago, IL)

**Appl. No.:** 16/693312

**Filed:** November 24, 2019

#### Prior Publication Data

Document Identifier	Publication Date
US 20200085771 A1	Mar. 19, 2020

#### Related U.S. Application Data

continuation parent-doc US 16103815 20180814 US 10512620 child-doc US 16693312

---

#### Publication Classification

**Int. Cl.:** A61K31/18 (20060101); A61K9/00 (20060101); A61K9/19 (20060101); A61P9/06 (20060101)

**U.S. Cl.:**

**Field of Classification Search****CPC:**    A61K (31/18); A61K (9/0019); A61P (9/06)**References Cited****U.S. PATENT DOCUMENTS**

<b>Patent No.</b>	<b>Issued Date</b>	<b>Patentee Name</b>	<b>U.S. Cl.</b>	<b>CPC</b>
6043273	12/1999	Duhaylongsod	N/A	N/A
6060454	12/1999	Duhaylongsod	N/A	N/A
6101412	12/1999	Duhaylongsod	N/A	N/A
6124363	12/1999	Appleby et al.	N/A	N/A
6136327	12/1999	Gupta et al.	N/A	N/A
6281246	12/2000	Sankaranarayanan	N/A	N/A
6369114	12/2001	Weil et al.	N/A	N/A
6482811	12/2001	Bacaner et al.	N/A	N/A
6491039	12/2001	Dobak, III	N/A	N/A
6500459	12/2001	Chhabra et al.	N/A	N/A
6544981	12/2002	Stein et al.	N/A	N/A
6627223	12/2002	Percel et al.	N/A	N/A
6632217	12/2002	Harper et al.	N/A	N/A
6645524	12/2002	Midha et al.	N/A	N/A
6720001	12/2003	Chen et al.	N/A	N/A
6800668	12/2003	Odidi et al.	N/A	N/A
6899700	12/2004	Gehling et al.	N/A	N/A
6916813	12/2004	Atwal et al.	N/A	N/A
7004171	12/2005	Benita et al.	N/A	N/A
7005425	12/2005	Belardinelli et al.	N/A	N/A
7005436	12/2005	Lloyd et al.	N/A	N/A
7022343	12/2005	Philbrook et al.	N/A	N/A
7048945	12/2005	Percel et al.	N/A	N/A
7090830	12/2005	Hale et al.	N/A	N/A
7179597	12/2006	Woosley	N/A	N/A
7289847	12/2006	Gill et al.	N/A	N/A
7341737	12/2007	Gehling et al.	N/A	N/A
7371254	12/2007	Dobak, III	N/A	N/A
7396524	12/2007	Yan	N/A	N/A
7417038	12/2007	Anker et al.	N/A	N/A
7526335	12/2008	Ferek-Petric	N/A	N/A
7538092	12/2008	Orlando et al.	N/A	N/A
7572776	12/2008	Yu et al.	N/A	N/A
7674820	12/2009	Fedida et al.	N/A	N/A
7745665	12/2009	Gant et al.	N/A	N/A
7765110	12/2009	Koneru	N/A	N/A
7776844	12/2009	Yu et al.	N/A	N/A
7815936	12/2009	Hasenzahl et al.	N/A	N/A
7829573	12/2009	Curwen et al.	N/A	N/A

7846968	12/2009	Chien et al.	N/A	N/A
7885824	12/2010	Koneru	N/A	N/A
7885827	12/2010	Koneru	N/A	N/A
7951183	12/2010	Dobak, III	N/A	N/A
8106099	12/2011	Brendel et al.	N/A	N/A
8236782	12/2011	Mosher et al.	N/A	N/A
8263125	12/2011	Vaya et al.	N/A	N/A
8268352	12/2011	Vaya et al.	N/A	N/A
8313757	12/2011	van Lengerich	N/A	N/A
8377994	12/2012	Gray et al.	N/A	N/A
8399018	12/2012	Lichter et al.	N/A	N/A
8440168	12/2012	Yang et al.	N/A	N/A
8465769	12/2012	Petereit et al.	N/A	N/A
8466277	12/2012	Orlando et al.	N/A	N/A
8575348	12/2012	Rao et al.	N/A	N/A
8696696	12/2013	Solem	N/A	N/A
8709076	12/2013	Matheny et al.	N/A	N/A
8753674	12/2013	Helson	N/A	N/A
8828432	12/2013	van Lengerich	N/A	N/A
8865213	12/2013	Sheth et al.	N/A	N/A
8871452	12/2013	Lee	N/A	N/A
8906847	12/2013	Cleemann et al.	N/A	N/A
8962574	12/2014	Reilly	N/A	N/A
8987262	12/2014	Leaute-Labreze et al.	N/A	N/A
9011526	12/2014	Matheny	N/A	N/A
9016221	12/2014	Brennan et al.	N/A	N/A
9044319	12/2014	Matheny	N/A	N/A
9060969	12/2014	Matheny	N/A	N/A
9078929	12/2014	Kuebelbeck et al.	N/A	N/A
9161952	12/2014	Matheny et al.	N/A	N/A
9239333	12/2015	Snider	N/A	N/A
9255104	12/2015	Rao et al.	N/A	N/A
9308084	12/2015	Matheny	N/A	N/A
9399067	12/2015	Mosher et al.	N/A	N/A
9474719	12/2015	Mullen et al.	N/A	N/A
9498481	12/2015	Rao et al.	N/A	N/A
9549912	12/2016	Milner et al.	N/A	N/A
9554989	12/2016	Kaplan et al.	N/A	N/A
9585851	12/2016	Yun et al.	N/A	N/A
9585884	12/2016	Rao et al.	N/A	N/A
9597302	12/2016	Yan et al.	N/A	N/A
9616026	12/2016	Singh	N/A	N/A
9682041	12/2016	Helson	N/A	N/A
9724297	12/2016	Thomas et al.	N/A	N/A
9770514	12/2016	Ghebre-Sellassie et al.	N/A	N/A
9889148	12/2017	Daemmgen et al.	N/A	N/A
9995756	12/2017	Saffitz et al.	N/A	N/A
10117881	12/2017	Helson	N/A	N/A
10238602	12/2018	Helson et al.	N/A	N/A
10258691	12/2018	Helson et al.	N/A	N/A

10349884	12/2018	Helson et al.	N/A	N/A
10357458	12/2018	Helson	N/A	N/A
10449193	12/2018	Helson et al.	N/A	N/A
10450267	12/2018	Stancl	N/A	N/A
10512620	12/2018	Somberg et al.	N/A	N/A
10537588	12/2019	Daemmgen et al.	N/A	N/A
10603316	12/2019	Xiong et al.	N/A	N/A
10617639	12/2019	Helson	N/A	N/A
10793519	12/2019	Somberg et al.	N/A	N/A
10799138	12/2019	Ivaturi et al.	N/A	N/A
10888524	12/2020	Yenkar et al.	N/A	N/A
10888552	12/2020	Rothman	N/A	N/A
11286235	12/2021	Somberg et al.	N/A	N/A
11344518	12/2021	Somberg	N/A	N/A
11583216	12/2022	Ivaturi et al.	N/A	N/A
11610660	12/2022	Devlin et al.	N/A	N/A
11696902	12/2022	Somberg et al.	N/A	N/A
2007/0009564	12/2006	McClain et al.	N/A	N/A
2007/0009654	12/2006	McClain et al.	N/A	N/A
2012/0003318	12/2011	Schuler et al.	N/A	N/A
2014/0235631	12/2013	Bunt et al.	N/A	N/A
2014/0276404	12/2013	Orlowski	N/A	N/A
2015/0081010	12/2014	Matheny	N/A	N/A
2015/0210712	12/2014	Blumberg et al.	N/A	N/A
2016/0082159	12/2015	Orlowski	N/A	N/A
2016/0128944	12/2015	Chawrai et al.	N/A	N/A
2016/0228379	12/2015	Kumar et al.	N/A	N/A
2016/0271070	12/2015	Singh et al.	N/A	N/A
2016/0271157	12/2015	Ahmed et al.	N/A	N/A
2016/0303133	12/2015	Dudley et al.	N/A	N/A
2016/0317388	12/2015	Bhargava et al.	N/A	N/A
2017/0049705	12/2016	Mateescu et al.	N/A	N/A
2017/0087105	12/2016	Yan et al.	N/A	N/A
2017/0100387	12/2016	Arora et al.	N/A	N/A
2017/0119627	12/2016	Bhargava et al.	N/A	N/A
2017/0157076	12/2016	Yacoby-Zeevi et al.	N/A	N/A
2017/0231885	12/2016	Cremers et al.	N/A	N/A
2017/0258781	12/2016	Noujaim et al.	N/A	N/A
2017/0296493	12/2016	Thomas et al.	N/A	N/A
2017/0348303	12/2016	Bosse et al.	N/A	N/A
2018/0071390	12/2017	Patel et al.	N/A	N/A
2019/0307343	12/2018	Ivaturi	N/A	A61B 5/046
2019/0352257	12/2018	Somberg et al.	N/A	N/A
2019/0380605	12/2018	Ivaturi et al.	N/A	N/A
2019/0388371	12/2018	Somberg	N/A	N/A
2019/0389888	12/2018	McChesney et al.	N/A	N/A
2020/0085771	12/2019	Somberg et al.	N/A	N/A
2020/0093759	12/2019	Somberg et al.	N/A	N/A
2020/0226481	12/2019	Sim et al.	N/A	N/A

2020/0253903	12/2019	Somberg	N/A	N/A
2020/0338027	12/2019	Somberg	N/A	N/A
2020/0383941	12/2019	Brelidze et al.	N/A	N/A
2021/0076959	12/2020	Ivaturi et al.	N/A	N/A
2021/0107867	12/2020	Somberg et al.	N/A	N/A
2021/0283049	12/2020	Somberg	N/A	N/A
2021/0346325	12/2020	Somberg	N/A	N/A
2022/0142954	12/2021	Somberg	N/A	N/A
2022/0241225	12/2021	Somberg	N/A	N/A
2022/0339130	12/2021	Somberg et al.	N/A	N/A
2023/0075398	12/2022	Devlin et al.	N/A	N/A
2023/0172883	12/2022	Kashfian et al.	N/A	N/A
2023/0187049	12/2022	Devlin et al.	N/A	N/A
2023/0225664	12/2022	Ivaturi et al.	N/A	N/A
2023/0225997	12/2022	Kashfian	N/A	N/A
2023/0248674	12/2022	Kashfian	N/A	N/A
2023/0255908	12/2022	Kashfian	N/A	N/A
2023/0255909	12/2022	Kashfian	N/A	N/A
2023/0270940	12/2022	Devlin et al.	N/A	N/A
2023/0285273	12/2022	Kashfian	N/A	N/A
2023/0293426	12/2022	Kashfian	N/A	N/A
2023/0293455	12/2022	Somberg et al.	N/A	N/A
2023/0310745	12/2022	Kashfian	N/A	N/A
2023/0372268	12/2022	Kashfian	N/A	N/A
2024/0156758	12/2023	Somberg	N/A	N/A
2024/0261242	12/2023	Kashfian	N/A	N/A
2025/0140361	12/2024	Kashfian et al.	N/A	N/A
2025/0152529	12/2024	Somberg et al.	N/A	N/A
2025/0152530	12/2024	Somberg et al.	N/A	N/A
2025/0213504	12/2024	Kashfian et al.	N/A	N/A

#### FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
737668	12/2000	AU	N/A
765269	12/2002	AU	N/A
2003233653	12/2002	AU	N/A
2005299693	12/2005	AU	N/A
2010231494	12/2010	AU	N/A
2013203252	12/2012	AU	N/A
2013381856	12/2014	AU	N/A
2011289176	12/2014	AU	N/A
2016266020	12/2017	AU	N/A
2017357916	12/2018	AU	N/A
2016313439	12/2018	AU	N/A
2015269699	12/2019	AU	N/A
0898964	12/1998	EP	N/A
1027329	12/2002	EP	N/A
1467705	12/2003	EP	N/A
1474105	12/2003	EP	N/A
1605976	12/2004	EP	N/A

2429291	12/2011	EP	N/A
1501467	12/2011	EP	N/A
2238127	12/2011	EP	N/A
2238128	12/2011	EP	N/A
2228065	12/2011	EP	N/A
2797556	12/2013	EP	N/A
2861254	12/2014	EP	N/A
3100728	12/2015	EP	N/A
2999461	12/2016	EP	N/A
2714011	12/2017	EP	N/A
1951210	12/2017	EP	N/A
9921829	12/1998	WO	N/A
03020240	12/2002	WO	N/A
03059318	12/2002	WO	N/A
2004082716	12/2003	WO	N/A
2007053393	12/2006	WO	N/A
2010132711	12/2009	WO	N/A
2012167212	12/2012	WO	N/A
2013185764	12/2012	WO	N/A
2014133539	12/2013	WO	N/A
2014143108	12/2013	WO	N/A
2014186843	12/2013	WO	N/A

## OTHER PUBLICATIONS

Barbey, J.T., et al., "Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects," *Clin. Pharmacol. Ther.* 66(1):91-99, Mosby, Inc., United States (1999). cited by applicant

Ho, D.S.W., et al., "Rapid intravenous infusion of d-l sotalol: time to onset of effects on ventricular refractoriness, and safety," *European Heart Journal* 16:81-86, European Society of Cardiology, United Kingdom (1995). cited by applicant

Läer, S., et al., "Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia," *J. American College of Cardiology* 46(7):1322-1330, Elsevier, Inc., United States (2005). cited by applicant

Lynch, J.J., et al., "Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death," *American Heart Journal* 109(5):949-958, Elsevier, Inc., United States (1985). cited by applicant

Neumar, R. W., et al., "Part 8: Adult Advanced Cardiovascular Life Support," *Circulation* 122(3):S729-S767 (2010). cited by applicant

Snider, M., et al., "Initial experience with antiarrhythmic medication monitoring by clinical pharmacists in an outpatient setting: a retrospective review," *Clinical Therapeutics* 31(6):1209-1218, Excerpta Medica, Inc., United States (2009). cited by applicant

Somberg, J.C., et al., "Developing a Safe Intravenous Sotalol Dosing Regimen," *American Journal of Therapeutics* 17:365-372, Lippincott Williams & Wilkins, United States (2010). cited by applicant

Somberg, J.C., et al., "Gender Differences in Cardiac Repolarization Following Intravenous Sotalol Administration," *J. Cardiovasc. Pharmacol. Ther.* 17(1):86-92, Sage, United States (2012). cited by applicant

Yarlagadda, B., et al., "Safety and Efficacy of Inpatient Initiation of Dofetilide Versus Sotalol for Atrial Fibrillation," *J. Atrial Fibrillation* 10(4):1805, Cardiofront, United States (2017). cited by

applicant

El-Assaad, I., et al., "Lone Pediatric Atrial Fibrillation in the United States: Analysis of Over 1500 Cases," *Pediatr. Cardiol.* 38:1004-1009, Springer Publishing, United States (2017). cited by applicant

Galloway, C.D., et al., "Development and Validation of a Deep-Learning Model to Screen for Hyperkalemia From the Electrocardiogram," *JAMA Cardiol.*: E1-E9, American Medical Association, United States (Apr. 3, 2019). cited by applicant

Hannun, A.Y., et al., "Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network," *Nature Medicine* 25:65-69, Nature Publishing, United States (Jan. 2019). cited by applicant

Marill, K.A., et al., "Meta-analysis of the Risk of Torsades de Pointes in Patients Treated with Intravenous Racemic Sotalol," *Academic Emergency Medicine* 8(2):117-124, Wiley, United States (2001). cited by applicant

Peters, F.P.J., et al., "Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide," *Netherlands Journal of Medicine* 53:93-96, Elsevier Science B.V., Netherlands (1998). cited by applicant

Radford, D.J., et al., "Atrial Fibrillation in Children," *Pediatrics* 59(2):250-256, American Academy of Pediatrics, United States (1977). cited by applicant

Thomas, S.P., et al., "Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: A randomized, digoxin-controlled trial," *Am. Heart J.* 147:e3 (6 pages), Elsevier Inc., Netherlands (2004). cited by applicant

U.S. Appl. No. 16/376,706, filed Apr. 5, 2019, U.S. Patent and Trademark Office, Alexandria, VA [unpublished]. cited by applicant

Li et al., "Efficacy of Intravenous Sotalol for Treatment of Incessant Tacharrhythmias in Children," *Am J Cardiol* 2017; 119: 1366-1370. cited by applicant

Saul et al., "Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tacharrhythmia," *Clinical Pharmacology and Therapeutics*, Mar. 2001. cited by applicant

Batul et al., "Intravenous Sotalol- Reintroducing a Forgotten Agent to the Electrophysiology Therapeutic Arsenal," *Journal of Atrial Fibrillation*, Feb.-Mar. 2017, vol. 9, Issue 5. cited by applicant

(Ivaturi, Vijay et al.) U.S. Appl. No. 16/376,706, filed Apr. 5, 2019, Specification, Claims, Figures. cited by applicant

(Ivaturi, Vijay et al.) U.S. Appl. No. 16/549,620, filed Aug. 23, 2019, Specification, Claims, Figures and File History as of Dec. 2020, 77 pages (abandoned). cited by applicant

(Ivaturi, Vijay et al.) U.S. Appl. No. 17/003,297, filed Aug. 26, 2020, Specification, Claims, Figures. cited by applicant

(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/103,815, filed Aug. 14, 2018, Specification, Claims, Figures. cited by applicant

(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/693,310, filed Nov. 24, 2019, Specification, Claims, Figures. cited by applicant

(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 16/726,361, filed Dec. 24, 2019, Specification, Claims, Figures. cited by applicant

(Somberg, John) Co-Pending U.S. Appl. No. 16/849,099, filed Apr. 15, 2020, Specification and Claims. cited by applicant

(Somberg, John) Co-Pending U.S. Appl. No. 16/863,567, filed Apr. 30, 2020, Specification and Claims. cited by applicant

(Somberg, John) Co-Pending U.S. Appl. No. 16/946,941, filed Jul. 13, 2020, Specification and Claims. cited by applicant

Campbell, T.J., "Intravenous sotalol for the treatment of atrial fibrillation and flutter after

cardiopulmonary bypass comparison with disopyramide and digoxin in a randomised trial,” BR Heart J. (1985) 54:86-90. cited by applicant

Co-Pending U.S. Appl. No. 16/103,815, Final Office Action dated Aug. 13, 2019, 13 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/103,815, Non-Final Office Action dated Feb. 6, 2019, 9 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/103,815, Notice of Allowance dated Oct. 30, 2019, 12 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/103,815, Response to Aug. 13, 2019 Final Office Action, filed Oct. 17, 2019, 10 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/103,815, Response to Dec. 13, 2018 Restriction Requirement, filed Dec. 31, 2018, 3 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/103,815, Response to Feb. 6, 2019 Non-Final Office Action, filed May 6, 2019, 17 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/103,815, Restriction Requirement dated Dec. 13, 2018, 6 pages. cited by applicant

Co-pending U.S. Appl. No. 16/376,706, Final Office Action dated Mar. 27, 2020, 12 pages. cited by applicant

Co-pending U.S. Appl. No. 16/376,706, Non-final Office Action dated Nov. 12, 2019, 12 pages. cited by applicant

Co-pending U.S. Appl. No. 16/376,706, Notice of Allowance and Examiner Initiated Interview Summary dated Jun. 10, 2020, 8 pages. cited by applicant

Co-pending U.S. Appl. No. 16/376,706, Response to Mar. 27, 2020 Final Office Action dated May 27, 2020, 11 pages. cited by applicant

Co-pending U.S. Appl. No. 16/376,706, Response to Nov. 12, 2019 Non-Final Office Action filed Feb. 12, 2020, 10 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/693,310, Non-Final Office Action dated Feb. 7, 2020, 12 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/693,310, Response to Feb. 7, 2020 Non-Final Office Action, filed May 5, 2020, 20 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/849,099, Final Office Action dated Feb. 3, 2021, 24 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/849,099, Non-Final Office Action dated Jul. 9, 2020, 19 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/849,099, Response to July 9, 2020 Non-Final Office Action, dated Dec. 9, 2020, 10 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Final Office Action dated Dec. 28, 2020, 17 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Non-Final Office Action dated Jun. 4, 2020, 18 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Response to Jun. 4, 2020 Non-Final Office Action dated Dec. 4, 2020, 10 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Response to May 13, 2020 Restriction Requirement, filed May 26, 2020, 44 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Restriction Requirement dated May 13, 2020, 5 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/946,941, Preliminary Amendment filed Jan. 20, 2021, 3 pages. cited by applicant

Dahmane, E., “Clinical Pharmacology-Driven Research to Optimize Bedside Therapeutics of Sotalol Therapy,” Clin Transl Sci (2019) 12:648-656. cited by applicant



FDA Highlights of Prescribing Information sotalol hydrochloride injection (2009), [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/022306s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022306s000lbl.pdf). cited by applicant

FDA Highlights of Prescribing Information Sotalolol (sotalol hydrochloride) (2014), [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2014/205108s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205108s000lbl.pdf). cited by applicant

Gomes, J.A., "Oral d,l Sotalol reduces the incidence of postoperative atrial fibrillation in coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled study," *J. Am. Coll. Cardio.* 34(2):334-9 (1999). cited by applicant

Kerin, Nicholas A., "Intravenous Sotalol: an under used treatment strategy," *Cardiology* (2018) 140:143-145. cited by applicant

Li, X., "Pediatric dosing of intravenous sotalol based on body surface area in patients with arrhythmia," *Pediatr Cardiol* (2017) 38:1450-1455. cited by applicant

Patel, A., "Is Sotalol more effective than standard beta-blockers for prophylaxis of atrial fibrillation during cardiac surgery?" *Interactive CardioVascular and Thoracic Surgery* 4 (2005) 147-50. cited by applicant

Peters, N.S., "Post-cardioversion atrial fibrillation: the synthesis of modern concepts?" *European Heart J.* (2000) 21, 1119-1121. cited by applicant

Sanjuan, R., "Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery," *Ann Thorac Surg* (2004) 77:838-43. cited by applicant

Somberg, J.C., "QT prolongation and serum sotalol concentration are highly correlated following intravenous and oral sotalol," *Cardiology* (2010) 116(3):219-25. cited by applicant

Tse, H.F., "Atrial pacing for suppression of early reinitiation of atrial fibrillation after successful internal cardioversion," *European Heart J.* (2000) 21, 1167-1176. cited by applicant

U.S. Appl. No. 16/376,706 (U.S. Pat. No. 10,799,138), file history Dec. 2020, 151 pages. cited by applicant

Valdes, S.O., "early experience with intravenous sotalol in children with and without congenital heart disease," *Heart Rhythm* 15(12): 1862-1869, Elsevier Inc., (Jul. 9, 2018). cited by applicant

(Somberg, John) Co-Pending U.S. Appl. No. 17/306,490, filed May 3, 2021, Specification and Claims. cited by applicant

U.S. Appl. No. 17/003,297, Preliminary Amendment filed Dec. 8, 2020, 9 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/693,310, Final Office Action dated Sep. 3, 2021, 20 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/693,310, Petition Decision dated Mar. 29, 2021, 2 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Non-Final Office Action and Examiner Initiated Interview Summary dated Jun. 9, 2021, 14 pages. cited by applicant

Hoffman et al. "Renal Insufficiency and Medication in Nursing Homes" *Medicine Deutsches Arzteblatt International* 2016; 113: 92-98. cited by applicant

(Devlin, Jodi) Co-pending U.S. Appl. No. 17/566,840, filed Dec. 31, 2021, Specification, Claims, and Figures. cited by applicant

(Somberg, John) Co-Pending U.S. Appl. No. 17/585,190, filed Jan. 26, 2022, Specification and Claims. cited by applicant

(Somberg, John) Co-Pending U.S. Appl. No. 17/725,189, filed Apr. 20, 2022, Specification and Claims. cited by applicant

U.S. Appl. No. 17/003,297, Non-Final Office Action dated Mar. 14, 2022, 14 pages. cited by applicant

U.S. Appl. No. 17/003,297, Response to Mar. 14, 2022 Non-Final Office Action, dated Jun. 15, 2022, 12 pages. cited by applicant

Batra, Anjan S., et al., "Junctional ectopic tachycardia: Current strategies for diagnosis and management," *Progress in Pediatric Cardiology*, 35 (2013) 49-54. cited by applicant

Blair, Andrew D., et al., Sotalol kinetics in renal insufficiency, *Clin. Pharmacol. Ther.*, 457-463

(Apr. 1981) (7 pages). cited by applicant

Borquez, Alejandro A., et al., "Intravenous Sotalol in the Young, Safe and Effective Treatment With Standardized Protocols," JACC: Clinical Electrophysiology, vol. 6, No. 4, Apr. 2020:425-32 (2020). cited by applicant

CHOC Children's, "Junctional Ectopic Tachycardia (JET) Care Guideline for Cardiovascular Intensive Care Unit (CVICU)," Sep. 18, 2019. cited by applicant

Cilliers, Antionette M., et al., "Junctional ectopic tachycardia in six paediatric patients," Heart; 78:413-415 (1997). cited by applicant

Co-Pending U.S. Appl. No. 16/693,310, Response to Sep. 3, 2021 Final Office Action, dated Feb. 3, 2022, 7 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/849,099, Notice of Abandonment, Aug. 20, 2021, 2 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Advisory Action dated Dec. 30, 2021, 11 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Final Office Action dated Oct. 26, 2021, 11 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Response to Jun. 9, 2021 Non-Final Office Action dated Oct. 12, 2021, 8 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/863,567, Response to Oct. 26, 2021 Final Office Action, dated Dec. 10, 2021, 8 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/946,941, Non-Final Office Action dated Feb. 7, 2022, 15 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/946,941, Notice of Allowance dated Apr. 4, 2022, 9 pages. cited by applicant

Co-Pending U.S. Appl. No. 16/946,941, Response to Feb. 7, 2022 Non-Final Office Action, dated Mar. 8, 2022, 6 pages. cited by applicant

Co-pending U.S. Appl. No. 17/566,840, Non-Final Office Action dated Mar. 23, 2022, 11 pages. cited by applicant

Co-pending U.S. Appl. No. 17/566,840, Petition Under 37 CFR 1.181 and Preliminary Amendment, dated Feb. 22, 2022, 9 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/585,190, Preliminary Amendment dated Mar. 4, 2022, 4 pages. cited by applicant

Dumas, M. et al., "Variations of sotalol kinetics in renal insufficiency", International Journal of Clinical Pharmacology, Therapy, and Toxicology, Oct. 1, 1989, 27(10), Abstract only. cited by applicant

Learn the Heart, "Antiarrhythmic Drug Review," <https://www.healio.com/cardiology/learn-the-heart/cardiology-review/topic-reviews/antiarrhythmic-drugs> (Year: 2022). cited by applicant

Maragnes, P., et al., "Usefulness of oral sotalol for the treatment of junctional ectopic tachycardia," Int'l J. of Cardiology, 35 (1995) 165-167. cited by applicant

Sundquist, H.K. et al., "Serum levels and half-life of sotalol in chronic renal failure", Annals of Clinical Research, Dec. 1, 1975, 7(6), Abstract Only. cited by applicant

(Devlin, Jodi) Co-pending U.S. Appl. No. 18/107,785, filed Feb. 9, 2023, Specification, Claims, and Figures. cited by applicant

(Devlin, Jodi) Co-pending U.S. Appl. No. 18/121,980, filed Mar. 15, 2023, Specification, Claims, and Figures. cited by applicant

(Ivaturi, Vijay et al.) U.S. Appl. No. 18/156,092, filed Jan. 18, 2023, Specification, Claims, Figures. cited by applicant

(Kashfian, Brandon Ira et al.) Co-Pending U.S. Appl. No. 17/892,301, filed Aug. 22, 2022, Specification and Claims. cited by applicant

(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/126,561, filed Mar. 27, 2023, Specification

and Claims. cited by applicant  
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 17/861,226, filed Jul. 10, 2022, Specification, Claims, Figures. cited by applicant  
U.S. Appl. No. 17/003,297, Final Office Action dated Jul. 27, 2022, 16 pages. cited by applicant  
U.S. Appl. No. 17/003,297, Notice of Allowance dated Oct. 18, 2022, 7 pages. cited by applicant  
U.S. Appl. No. 17/003,297, Response to Final Office Action dated Sep. 27, 2022, 12 pages. cited by applicant  
Boriani, G. et al., Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation. International Journal of Cardiology. 2004; 95, 245-250. cited by applicant  
Cantillon, D. J. and Amuthan, R. "Atrial Fibrillation", Cleveland Clinic: Center for Continuing Education, Disease Management:  
<https://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/atrial-fibrillation/>, Aug. 2018, 18 pages. cited by applicant  
Co-Pending U.S. Appl. No. 16/693,310, Non-Final Office Action dated Jul. 21, 2022, 16 pages. cited by applicant  
Co-Pending U.S. Appl. No. 16/693,310, Notice of Allowance dated Mar. 9, 2023, 7 pages. cited by applicant  
Co-Pending U.S. Appl. No. 16/693,310, Response to Jul. 21, 2022 Non-Final Office Action including Rule 132 Affidavit, dated Jan. 20, 2023, 15 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/306,490, Preliminary Amendment filed Dec. 7, 2022, 38 pages. cited by applicant  
Co-pending U.S. Appl. No. 17/566,840, Notice of Allowance dated Jul. 25, 2022, 7 pages. cited by applicant  
Co-pending U.S. Appl. No. 17/566,840, Notice of Allowance dated Nov. 9, 2022, 7 pages. cited by applicant  
Co-pending U.S. Appl. No. 17/566,840, Response to Mar. 23, 2022 Non-Final Office Action, dated Jul. 7, 2022, 10 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/861,226, Preliminary Amendment dated Jul. 10, 2022, 4 pages. cited by applicant  
FDA "Highlights of Prescribing Information" for sotalol hydrochloride injection, Revised Mar. 2020, 16 pages, [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2020/022306s005lblrpl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022306s005lblrpl.pdf). cited by applicant  
Le Coz, F. et al. Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization. Clin Pharmacol Ther 1995; 57:533. cited by applicant  
Procainamide Dosage. Drugs.com. Last updated Sep. 13, 2021. 3 pages. cited by applicant  
Rasmussen, H.S. et al., Dofetilide, A Novel Class III Antiarrhythmic Agent, J Cardiovasc Pharmacol. 1992;20 Suppl 2:S96-105. cited by applicant  
Rosseau, M. F., Cardiac and Hemodynamic Effects of Intravenous Dofetilide in Patients With Heart Failure, Am J Cardiol 2001;87:1250-1254. cited by applicant  
Sedgwick, M. et al., Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug, Br. J. Clin. Pharmac. (1991), 31, 515-519. cited by applicant  
Somberg, et al., "Sotalol versus Amiodarone in Treatment of Atrial Fibrillation," J. Atrial Fibrillation, Feb.-Mar. 2016, vol., Issue 5. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/135,467, filed Apr. 17, 2023, Specification and Claims. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/304,196, filed Apr. 20, 2023, Specification and Claims. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/306,660, filed Apr. 25, 2023, Specification

and Claims. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/315,790, filed May 11, 2023, Specification and Claims. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/321,220, filed May 22, 2023, Specification and Claims. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/323,337, filed May 24, 2023, Specification and Claims. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/324,703, filed May 26, 2023, Specification and Claims. cited by applicant  
(Somberg, John C. et al.) Co-Pending U.S. Appl. No. 18/322,111, filed May 23, 2023, Specification, Claims, Figures. cited by applicant  
(Somberg, John) Co-Pending U.S. Appl. No. 18/417,748, filed Jan. 19, 2024, Specification and Claims. cited by applicant  
Co-Pending U.S. Appl. No. 17/585,190, Restriction Requirement dated Oct. 19, 2023, 5 pages. cited by applicant  
Co-pending U.S. Appl. No. 18/121,980, Preliminary Amendment dated Jul. 18, 2023, 6 pages. cited by applicant  
Co-Pending U.S. Appl. No. 18/322,111, Preliminary amendment dated Jan. 31, 2024, 7 pages. cited by applicant  
Falk, Rodney H. et al, Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter, JACC vol. 29, No. 2, 385-90 (Feb. 1997). cited by applicant  
Von Bergen, N. H. et al. "Outpatient intravenous sotalol load to replace 3-day admission oral sotalol load", Heart Rhythm Case Reports (Jul. 2019), vol. 5, issue 7, p. 382-383. cited by applicant  
(Kashfian, Brandon Ira) Co-Pending U.S. Appl. No. 18/631,538, filed Apr. 10, 2024, Specification and Claims. cited by applicant  
U.S. Appl. No. 18/156,092, Response to Notice to File Missing Parts and Preliminary Amendment, dated Apr. 4, 2023, 6 pages. cited by applicant  
Co-pending U.S. Appl. No. 18/107,785, Preliminary Amendment dated Feb. 15, 2024, 10 pages. cited by applicant  
Co-Pending U.S. Appl. No. 18/417,748, Preliminary Amendment dated Apr. 22, 2024, 6 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/306,490, Non-Final Office Action dated Jun. 7, 2024, 50 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/306,490, Response to Jun. 7, 2024 Non-Final Office Action, dated Dec. 6, 2024, 9 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/725,189, Non-Final Office Action dated Jun. 18, 2024, 10 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/725,189, Response to Jun. 18, 2024 Non-Final Office Action, dated Dec. 18, 2024, 5 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/861,226, Non-Final Office Action dated Jul. 16, 2024, 17 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/861,226, Response to Jul. 16, 2024 Non-Final Office Action, dated Dec. 16, 2024, 9 pages. cited by applicant  
Co-Pending U.S. Appl. No. 17/892,301, Restriction Requirement dated Dec. 3, 2024, 6 pages. cited by applicant  
Somberg, John et al. Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion. *Cardiol Res.* 2020;11(5):294-304. cited by applicant  
Co-Pending U.S. Appl. No. 17/306,490, Response to Mar. 11, 2025 Final Office Action, dated Jun. 26, 2025, 6 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/725,189, Notice of Allowance dated Apr. 30, 2025, 9 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/861,226, Response to Mar. 21, 2025 Final Office Action, dated Jun. 23, 2025, 11 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/892,301, Notice of Allowance dated Jul. 11, 2025, 8 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/892,301, Response to Mar. 24, 2025 Non-Final Office Action, dated Jun. 24, 2025, 9 pages. cited by applicant

Co-pending U.S. Appl. No. 18/107,785, Non-Final Office Action dated May 8, 2025, 9 pages. cited by applicant

(Kashfian, Brandon Ira et al.) Co-Pending U.S. Appl. No. 19/009,774, filed Jan. 3, 2025, Specification, Drawings, and Claims. cited by applicant

(Kashfian, Brandon Ira et al.) Co-Pending U.S. Appl. No. 19/080,585, filed Mar. 14, 2025, Specification and Claims. cited by applicant

(Somberg, John et al.) Co-Pending U.S. Appl. No. 19/019,556, filed Jan. 14, 2025, Specification and Claims. cited by applicant

(Somberg, John et al.) Co-Pending U.S. Appl. No. 19/022,878, filed Jan. 15, 2025, Specification and Claims. cited by applicant

Bianconi, L. et al., Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter, European Heart Journal (2000) 21, 1265-1273, 9 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/306,490, Final Office Action dated Mar. 11, 2025, 13 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/861,226, Final Office Action dated Mar. 21, 2025, 24 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/861,226, Interview Summary dated Jan. 7, 2025, 2 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/892,301, Response to Dec. 3, 2024 Restriction Requirement, dated Mar. 3, 2025, 7 pages. cited by applicant

Co-Pending U.S. Appl. No. 17/892,301, Non-Final Office Action dated Mar. 24, 2025, 11 pages. cited by applicant

Co-Pending U.S. Appl. No. 19/019,556, Preliminary Amendment dated Jan. 14, 2025, 4 pages. cited by applicant

Dailymed Website, Tikosyn (dofetilide) Capsules, <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=02438044-d6a3-49e9-a1ac-3aad21ef2c8c> (Year: 1999), 21 pages. cited by applicant

Kerin, N. Z. and Jacob, S., The Efficacy of Sotalol in Preventing Postoperative Atrial Fibrillation: A Meta-Analysis, The American Journal of Medicine, vol. 124, No. 9, Sep. 2011, 9 pages. cited by applicant

---

*Primary Examiner:* Barsky; Jared

*Attorney, Agent or Firm:* New River Valley IP Law, P.C.

---

## **Background/Summary**

FIELD

(1) This disclosure provides methods of treating or preventing atrial fibrillation, atrial flutter, or a

combination thereof comprising intravenously administering sotalol hydrochloride to subject in need thereof.

## BACKGROUND

(2) Sotalol hydrochloride ("sotalol") is Vaughan Williams Class III anti-arrhythmic drug that prolongs cardiac action potential duration by blocking the outward potassium channel IKr (rapid potassium rectifier current), thereby prolonging repolarization time.

(3) Although sotalol is effective at treating or preventing atrial fibrillation, atrial flutter, and combinations thereof, sotalol's mechanism of action is both anti-arrhythmic and pro-arrhythmic. Too much sotalol too fast can lead to excessive prolongation of repolarization time giving rise to life threatening arrhythmias, especially Torsade de Pointes ventricular tachycardia (TdP). Thus, it is well understood in the art, that during sotalol's initial loading, or in a dose escalation intervention, it is critical to monitor a subject's QTc interval to avoid excessive QTc prolongation.

(4) Due to sotalol's potential to induce arrhythmia, the FDA has mandated in-hospital QTc monitoring for at least three days upon initial sotalol hydrochloride loading and for dose escalation. Although this extended hospital stay is effective at reducing subject risk, maintaining the subject in a telemetry unit for three days is extremely expensive, making sotalol a less desirable treatment choice in a managed care environment. A need therefore exists to develop methods of reducing the length of hospital stay required to safely and efficaciously administer sotalol to subjects in need thereof.

## BRIEF SUMMARY

(5) The present disclosure provides methods of safely intravenously administering sotalol hydrochloride to subjects in need thereof over a significantly reduced period of time, such as about 1 hour. In particular, the present disclosure provides a method of achieving a sotalol steady state C.sub.max after about 1 hour of intravenous administration equal to the sotalol steady state C.sub.max typically achieved after BID PO sotalol administration for three days.

(6) In one embodiment, this disclosure provides a method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride over a period of about 60 minutes.

(7) In some embodiments, the method further comprises discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(8) In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 750 ng/mL and about 850 ng/mL in the subject.

(9) In some embodiments, the method further comprises orally administering to the subject 80 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(10) In some embodiments, the method further comprises discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(11) In some embodiments, the method further comprises initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to intravenous sotalol administration.

(12) Also provided is a method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously

administering to the subject between about 1.23 mg/min and about 1.76 mg/min of sotalol hydrochloride over a period of about 60 minutes.

(13) In some embodiments, the method further comprises discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(14) In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1150 ng/mL and about 1250 ng/mL in the subject.

(15) In some embodiments, the method further comprises orally administering to the subject 120 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(16) In some embodiments, the method further comprises discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(17) In some embodiments, the method further comprises initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to intravenous sotalol administration.

(18) Also provided is a method of treating atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 1.65 mg/min to about 2.35 mg/min of sotalol hydrochloride over a period of about 60 minutes.

(19) In some embodiments, the method further comprises discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(20) In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1550 ng/mL and about 1650 ng/mL in the subject.

(21) In some embodiments, the method further comprises orally administering to the subject 160 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(22) In some embodiments, the method further comprises discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(23) In some embodiments, the method further comprises initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% the subject's QTc prior to intravenous sotalol administration.

(24) Also provided is a method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride over a period of about 60 minutes, wherein the subject received an administration of sotalol hydrochloride between about 12 hours and about 24 hours before the intravenous administration.

- (25) In some embodiments, the subject received an oral administration of 80 mg of oral sotalol hydrochloride between about 12 and about 24 hours before the intravenous administration.
- (26) In some embodiments, the method further comprises discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.
- (27) In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1150 ng/mL and about 1250 ng/mL in the subject.
- (28) In some embodiments, the method further comprises orally administering to the subject 120 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.
- (29) In some embodiments, the method further comprises discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.
- (30) In some embodiments, the method further comprises initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% the subject's QTc prior to intravenous sotalol administration.
- (31) Also provided is a method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 1.05 mg/min and 1.47 mg/min of sotalol hydrochloride over a period of about 60 minutes, wherein the subject received an administration of sotalol hydrochloride between about 12 hours and about 24 hours before the intravenous administration.
- (32) In some embodiments, the subject received an oral administration of 120 mg of oral sotalol hydrochloride between about 12 and about 24 hours before the intravenous administration.
- (33) In some embodiments, the method further comprises discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.
- (34) In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1550 ng/mL and about 1650 ng/mL in the subject.
- (35) In some embodiments, the method further comprises orally administering to the subject 160 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.
- (36) In some embodiments, the method further comprises discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.
- (37) In some embodiments, the method further comprises initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% the subject's QTc prior to intravenous sotalol administration.

---

## Description



## BRIEF DESCRIPTION OF THE DRAWINGS

- (1) The above-mentioned features and objects of this disclosure will become more apparent with reference to the following description taken in conjunction with the accompanying drawings.
- (2) FIG. 1 is a line graph depicting initiation of an intravenous dose of 55 mg of sotalol hydrochloride to achieve an estimated steady state C.sub.max equivalent to the steady state C.sub.max achieved via chronic oral twice daily dosing of 80 mg sotalol hydrochloride in a subject with normal renal function.
- (3) FIG. 2 is a line graph depicting dose escalation from 80 mg twice a day to 120 mg twice a day of oral sotalol hydrochloride via the intravenous administration of 55 mg of sotalol hydrochloride in 1 hour.

## DETAILED DESCRIPTION

### Definitions

- (4) As used in this disclosure, the term “or” is defined as a logical disjunction (i.e., and/or) and does not indicate an exclusive disjunction unless expressly indicated as such with the terms “either,” “unless,” “alternatively,” and words of similar effect.
- (5) As used herein, the term “about” means  $\pm 10\%$  of the value specified. By way of example only, “about 50” means from 45 to 55.
- (6) The term “C.sub.max” refers to the maximum blood concentration shown on the curve that represents changes in blood concentrations of an active pharmaceutical ingredient (e.g., sotalol hydrochloride), or a metabolite of the active pharmaceutical ingredient, over time.
- (7) The term “steady state C.sub.max” refers to the state, wherein the post dose maximum plasma concentration of sotalol hydrochloride does not differ from one dose to another. In some embodiments, the method described herein provides a steady state C.sub.max of sotalol hydrochloride concentration in a range between about 800 ng/mL and about 1600 ng/mL, depending upon the amount of sotalol dosed.
- (8) The term “QT” refers to a telltale measurement seen on an electrocardiogram (ECG). The QT interval is measured from the start of the Q wave or the QRS complex, to the end of the T wave, where the Q wave corresponds to the beginning of ventricular depolarization and the T wave end corresponds to the end of ventricular repolarization.
- (9) The term “QTc” refers to a calculated interval that represents the QT interval corrected for heart rate. The QTc interval may be derived by simple mathematical correlation of the QT interval and the heart rate. In preferred embodiments, and for purposes of the present disclosure, the QTc interval is measured using the Bazett formula. Other methods, however, are known in the art, such as the nomogram method, the Frederica formula, or the linear regression equation.
- (10) The term “ $\Delta$ QTc” refers to the difference between a QTc measurement taken prior to intravenous sotalol hydrochloride administration and a QTc measured after intravenous sotalol hydrochloride administration.
- (11) The term “PO” stands for “per os” and refers to an oral dosing regimen.
- (12) The term “BID” stands for “bis in die” and means twice a day.
- (13) The term “subject” refers to a human subject.
- (14) An “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response.
- (15) The terms “treat,” “treating,” and “treatment” refer to any indicia of success in the treatment or amelioration of an injury, disease, or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, disease, or condition more tolerable to the subject; slowing in the rate of degeneration or decline; or improving a subject's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subject parameters, including the results of a physical examination,

neuropsychiatric examinations, or psychiatric evaluation.

(16) Intravenous sotalol was approved by the FDA in 2009. Although FDA guidance requires a slow infusion over five hours coupled with multi-day cardiac monitoring, it has now been surprisingly discovered that it is possible to safely reach a sotalol steady state  $C_{sub,max}$  in a subject equal to the sotalol steady state  $C_{sub,max}$  typically achieved after BID PO sotalol administration for three days at various sotalol dosage strengths, after about 1 hour of intravenous administration. The ability to reach a steady state  $C_{sub,max}$  equal to the steady state  $C_{sub,max}$  achieved via oral dosing is surprising because rapid, intravenous sotalol administration was thought to result in high sotalol serum concentration, excessive QT interval prolongation, and on occasion, Torsade de Pointes ventricular tachycardia. See, Somberg, et. al., *Am. J. Ther.* 17(4):365-72 (2010).

(17) Sotalol Initiation Protocol in Naïve Subjects

(18) It has been surprisingly discovered that an about 55 mg to about 64 mg intravenous load of sotalol can be safely delivered over about 1 hour to reach a projected steady state  $C_{sub,max}$  of about 800 ng/mL (corresponding to the steady state  $C_{sub,max}$  achieved after three days of PO BID dosing of 80 mg sotalol hydrochloride) in sotalol naïve subjects. It has likewise been surprisingly discovered that an about 82 mg to about 96 mg intravenous load of sotalol hydrochloride delivered over about 1 hour can safely provide a projected steady state  $C_{sub,max}$  of about 1200 ng/mL (corresponding to the steady state  $C_{sub,max}$  achieved after three days of PO BID dosing of 120 mg sotalol hydrochloride) in sotalol naïve subjects and that an about 110 mg to about 128 mg intravenous load of sotalol hydrochloride delivered over about 1 hour can safely provide a projected steady state  $C_{sub,max}$  of about 1600 ng/mL (corresponding to the steady state  $C_{sub,max}$  achieved after three days of PO BID dosing of 160 mg sotalol hydrochloride) in naïve subjects. In each of these cases, intravenous administration of sotalol hydrochloride can be followed at appropriate intervals by oral sotalol hydrochloride to maintain the steady state  $C_{sub,max}$  for efficacious treatment or prevention of a given condition.

(19) By administering sotalol according to the dosing protocol described herein, a subject can be discharged from the hospital from about 18 hours to about 24 hours after initiation of intravenous sotalol administration. During the 18-24 hour period, the subject typically experiences at least two sotalol concentration peaks: one following intravenous sotalol hydrochloride administration and one following subsequent oral sotalol hydrochloride administration. In some embodiments, the subject experiences two sotalol concentration peaks over a period of about 15 hours to about 18 hours. In each instance, the subject's peak plasma concentration will approach the steady state  $C_{sub,max}$  observed during chronic dosing. As a result, it is possible to assess the QTc interval of a subject corresponding to the full concentration effect of sotalol hydrochloride over an 18-24 hour period and to determine within that period, if the subject can tolerate the dose.

(20) Accordingly, in some embodiments, this disclosure provides a method of safely administering sotalol hydrochloride to a subject in need thereof, the method comprising intravenously administering sotalol hydrochloride over a period of about 60 minutes to reach a sotalol steady state  $C_{sub,max}$  in the subject, wherein the subject has a QTc interval during the intravenous administration of sotalol hydrochloride that is less than or equal to 480 msec to 500 msec; and wherein the subject has a  $\Delta QTc$  during sotalol hydrochloride administration that is less than 20% of the subject's QTc prior to intravenous sotalol administration. In some embodiments, this disclosure provides a method of safely administering sotalol hydrochloride to a subject in need thereof, the method comprising intravenously administering sotalol hydrochloride over a period of about 60 minutes to reach a sotalol steady state  $C_{sub,max}$  in the subject, wherein the subject has a QTc interval during the intravenous administration of sotalol hydrochloride that is less than or equal to 480 msec; and wherein the subject has a  $\Delta QTc$  during sotalol hydrochloride administration that is less than 20% of the subject's QTc prior to intravenous sotalol administration. In other embodiments, this disclosure provides a method of safely administering sotalol hydrochloride to a subject in need thereof, the method comprising intravenously administering sotalol hydrochloride

over a period of about 60 minutes to reach a sotalol steady state C.sub.max in the subject, wherein the subject has a QTc interval during the intravenous administration of sotalol hydrochloride that is less than or equal to 500 msec; and wherein the subject has a  $\Delta$ QTc during sotalol hydrochloride administration that is less than 20% of the subject's QTc prior to intravenous sotalol administration.

(21) In some embodiments, about 49.5 to about 70.4 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C.sub.max of about 800 ng/mL. In a particular embodiment, about 55 mg to about 64 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C.sub.max of 800 ng/mL. In some embodiments, about 55 mg to about 64 mg of intravenous sotalol hydrochloride administered over about a 60 minute period can provide a sotalol steady state C.sub.max of between about 600 ng/mL and about 1000 ng/mL, between about 600 ng/mL and about 900 ng/mL, between about 600 ng/mL and about 850 ng/mL, between about 600 ng/mL and about 800 ng/mL, between about 600 ng/mL and about 750 ng/mL, between about 600 ng/mL and about 700 ng/mL, between about 700 ng/mL and about 1000 ng/mL, between about 700 ng/mL and about 900 ng/mL, between about 700 ng/mL and about 850 ng/mL, between about 700 ng/mL and about 800 ng/mL, between about 700 ng/mL and about 750 ng/mL, between about 750 ng/mL and about 1000 ng/mL, between about 750 ng/mL and about 900 ng/mL, between about 750 ng/mL and about 850 ng/mL, between about 750 ng/mL and about 800 ng/mL, between about 800 ng/mL and about 1000 ng/mL, between about 800 ng/mL and about 900 ng/mL, between about 800 ng/mL and about 850 ng/mL, between about 850 ng/mL and about 1000 ng/mL, between about 850 ng/mL and about 900 ng/mL, or between about 900 ng/mL and about 1000 ng/mL. In particular embodiments, an about 55 mg to about 64 mg intravenous load of sotalol hydrochloride administered over about 60 minutes can provide a steady state C.sub.max of between about 750 ng/mL and about 850 ng/mL.

(22) In some embodiments, between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride can be intravenously administered over the about 60 minute period to achieve the desired steady state C.sub.max.

(23) In another embodiment, about 73.8 to about 105.6 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C.sub.max of about 1200 ng/mL. In a particular embodiment, about 82 mg to about 96 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C.sub.max of about 1200 ng/mL. In some embodiments, about 82 mg to about 96 mg of intravenous sotalol hydrochloride administered over about 60 minutes can provide a steady state C.sub.max of between about 1000 ng/mL and about 1400 ng/mL, between about 1000 ng/mL and about 1300 ng/mL, between about 1000 ng/mL and about 1250 ng/mL, between about 1000 ng/mL and about 1200 ng/mL, between about 1000 ng/mL and about 1150 ng/mL, between about 1000 ng/mL and about 1100 ng/mL, between about 1100 ng/mL and about 1400 ng/mL, between about 1100 ng/mL and about 1300 ng/mL, between about 1100 ng/mL and about 1250 ng/mL, between about 1100 ng/mL and about 1200 ng/mL, between about 1100 ng/mL and about 1150 ng/mL, between about 1150 ng/mL and about 1400 ng/mL, between about 1150 ng/mL and about 1300 ng/mL, between about 1150 ng/mL and about 1250 ng/mL, between about 1150 ng/mL and about 1200 ng/mL, between about 1200 ng/mL and about 1400 ng/mL, between about 1200 ng/mL and about 1300 ng/mL, between about 1200 ng/mL and about 1250 ng/mL, between about 1250 ng/mL and about 1400 ng/mL, between about 1250 ng/mL and about 1300 ng/mL, or between about 1300 ng/mL and about 1400 ng/mL. In particular embodiments, about 82 mg to about 96 mg of sotalol hydrochloride administered intravenously over about 60 minutes can provide a steady state C.sub.max of between about 1150 ng/mL and about 1250 ng/mL.

(24) In some embodiments, an intravenous dose of between about 1.23 mg/min and about 1.76 mg/min of sotalol hydrochloride can be administered over a period of about 60 minutes to achieve the desired steady state C.sub.max.

(25) In yet another embodiment, about 99 to 140.8 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C.sub.max of about 1600 ng/mL. In a particular embodiment, about 110 mg to about 128 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C.sub.max of about 1600 ng/mL. In some embodiments, about 110 mg to about 128 mg of intravenous sotalol hydrochloride administered over a period of about 60 minutes can provide a steady state C.sub.max of between about 1400 ng/mL and about 1800 ng/mL, between about 1400 ng/mL and about 1700 ng/mL, between about 1400 ng/mL and about 1650 ng/mL, between about 1400 ng/mL and about 1600 ng/mL, between about 1400 ng/mL and about 1550 ng/mL, between about 1400 ng/mL and about 1500 ng/mL, between about 1500 ng/mL and about 1800 ng/mL, between about 1500 ng/mL and about 1700 ng/mL, between about 1500 ng/mL and about 1650 ng/mL, between about 1500 ng/mL and about 1600 ng/mL, between about 1500 ng/mL and about 1550 ng/mL, between about 1550 ng/mL and about 1800 ng/mL, between about 1550 ng/mL and about 1700 ng/mL, between about 1550 ng/mL and about 1650 ng/mL, between about 1550 ng/mL and about 1600 ng/mL, between about 1600 ng/mL and about 1800 ng/mL, between about 1600 ng/mL and about 1700 ng/mL, between about 1600 ng/mL and about 1650 ng/mL, between about 1650 ng/mL and about 1800 ng/mL, between about 1650 ng/mL and about 1700 ng/mL, or between about 1700 ng/mL and about 1800 ng/mL. In some embodiments, about 110 mg to about 128 mg of sotalol hydrochloride administered intravenously over about 60 minutes can provide a steady state C.sub.max of between about 1550 ng/mL and about 1650 ng/mL.

(26) In some embodiments, between about 1.65 mg/min and about 2.35 mg/min of sotalol hydrochloride can be intravenously administered over the about 60 minute period.

(27) Typically, for each of the embodiments described above, the QTc interval of a subject is measured 5 to 15 minutes prior to sotalol initiation and subsequently at 15 minute intervals during intravenous sotalol administration and for about 90 minutes after intravenous administration of sotalol hydrochloride is complete. In other embodiments, the QTc interval of a subject is monitored continuously via telemetry upon intravenous administration of sotalol hydrochloride up to about 90 minutes following complete administration of the drug. It is within the skill of an ordinarily skilled cardiologist to calculate  $\Delta$ QTc based on these measurements and to increase or decrease sotalol administration appropriately.

(28) In some embodiments, where a subject has been initiated on about 55 mg to about 64 mg of intravenous sotalol over about a 60 minute period, 80 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours after the completion of the intravenous administration of the about 55 mg to about 64 mg of sotalol hydrochloride. In some embodiments, 80 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours, between about 2 hours and about 5 hours, between about 2 hours and about 4 hours, between about 2 hours and about 3 hours, between about 3 hours and about 6 hours, between about 3 hours and about 5 hours, between about 3 hours and about 4 hours, between about 4 hours and about 6 hours, between about 4 hours and about 5 hours, or between about 5 hours and about 6 hours after the completion of the intravenous administration of about 55 mg to about 64 mg of sotalol hydrochloride.

(29) In some embodiments, between about 2 hours and 5 hours after oral administration of 80 mg of sotalol hydrochloride, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec to 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In some embodiments, between about 2 hours and 5 hours after oral administration of 80 mg of sotalol hydrochloride, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In other embodiments, between about 2 hours and 5 hours after oral administration of 80 mg of sotalol hydrochloride, further oral

administration is discontinued or reduced when the subject has a QTc interval that is greater than 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(30) Alternatively, and in another embodiment, a BID regimen of PO 80 mg sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after the initial oral administration of sotalol hydrochloride that is less than or equal to 480 msec to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In some embodiments, a BID regimen of PO 80 mg sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after the initial oral administration of sotalol hydrochloride that is less than or equal to 480 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In other embodiments, a BID regimen of PO 80 mg sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after the initial oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration.

(31) In another embodiment, such when the subject exhibits impaired renal function, i.e. a glomerular filtration rate (GFR) of between about 45-60 mL/min, the maintenance dose of oral sotalol can be administered over a longer dosing interval. For example, a once daily regimen of 80 mg PO sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of 80 mg of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration.

(32) In some embodiments, where a subject has been initiated on about 82 mg to about 96 mg of intravenous sotalol over about a 60 minute period, 120 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours after completion of the intravenous administration of the about 82 mg to about 96 mg of sotalol hydrochloride. In some embodiments, 120 mg of sotalol hydrochloride is administered orally between about 2 hours and about 6 hours, between about 2 hours and about 5 hours, between about 2 hours and about 4 hours, between about 2 hours and about 3 hours, between about 3 hours and about 6 hours, between about 3 hours and about 5 hours, between about 3 hours and about 4 hours, between about 4 hours and about 6 hours, between about 4 hours and about 5 hours, or between about 5 hours and about 6 hours after completion of the intravenous administration of about 82 mg to about 96 mg of sotalol hydrochloride.

(33) In some embodiments, between about 2 hours and 5 hours after oral administration of 120 mg of sotalol hydrochloride, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 to 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to initial oral administration of sotalol hydrochloride. In a particular embodiment, between about 2 hours and 5 hours after oral administration of 120 mg of sotalol hydrochloride, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to initial oral administration of sotalol hydrochloride. In another embodiment, between about 2 hours and 5 hours after oral administration of 120 mg of sotalol hydrochloride, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to initial oral administration of sotalol hydrochloride.

(34) Alternatively, and in another embodiment, a BID regimen of PO 120 mg sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol

administration. In a particular embodiment, a BID regimen of PO 120 mg sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 480 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In another embodiment, a BID regimen of PO 120 mg sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration.

(35) In another embodiment, such when the subject exhibits impaired renal function, i.e. a glomerular filtration rate (GFR) of between about 45-60 mL/min, the maintenance dose of oral sotalol can be administered over a longer dosing interval. For example, a once daily regimen of 120 mg PO sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of 120 mg of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration.

(36) In some embodiments, where a subject has been initiated on about 110 mg to about 128 mg of intravenous sotalol over about a 60 minute period, 160 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours after completion of the intravenous administration of about 110 mg to about 128 mg of sotalol hydrochloride. In some embodiments, 160 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours, between about 2 and about 5 hours, between about 2 and about 4 hours, between about 2 hours and about 3 hours, between about 3 hours and about 6 hours, between about 3 hours and about 5 hours, between about 3 hours and about 4 hours, between about 4 hours and about 6 hours, between about 4 hours and about 5 hours, or between about 5 hours and about 6 hours after completion of the intravenous administration of about 110 mg to about 128 mg of sotalol hydrochloride.

(37) In some embodiments, between about 2 hours and 5 hours after initial oral administration of 160 mg of sotalol hydrochloride, further oral administration can be discontinued or reduced when the subject has a QTc interval that is greater than 480 to 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In one embodiment, between about 2 hours and 5 hours after initial oral administration of 160 mg of sotalol hydrochloride, further oral administration can be discontinued or reduced when the subject has a QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In another embodiment, between about 2 hours and 5 hours after initial oral administration of 160 mg of sotalol hydrochloride, further oral administration can be discontinued or reduced when the subject has a QTc interval that is greater than 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(38) Alternatively, and in another embodiment, a BID regimen of PO of 160 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 480 to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In a particular embodiment, a BID regimen of PO of 160 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 480 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In another embodiment, a BID regimen of PO of 160 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol

administration.

(39) In another embodiment, such when the subject exhibits impaired renal function, i.e. a glomerular filtration rate (GFR) of between about 45-60 mL/min, the maintenance dose of oral sotalol can be administered over a longer dosing interval. For example, a once daily regimen of 160 mg PO sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of 160 mg of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration.

(40) Dose Escalation Protocol

(41) The method of rapid sotalol introduction described herein can also be applied to dose escalation, for example when a subject needs to transition from 80 mg BID PO to 120 mg BID PO; or from 120 mg BID PO to 160 mg BID PO.

(42) For example, subjects receiving 80 or 120 mg BID PO sotalol hydrochloride can be safely transitioned to 120 or 160 mg BID PO sotalol hydrochloride, respectively, via the administration of an intravenous infusion about 12 hours after the last oral dose of sotalol hydrochloride, i.e. when the concentration of sotalol hydrochloride is at a trough (steady state C.sub.min).

(43) Dose Escalation to from 80 mg to 120 mg Oral Sotalol Hydrochloride

(44) In some embodiments, about 49.5 to about 70.4 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C.sub.max of about 1200 ng/mL. In a particular embodiment, about 55 mg to about 64 mg of sotalol hydrochloride can be safely administered intravenously over a period of about 60 minutes to provide an average sotalol steady state C.sub.max of about 1200 ng/mL (corresponding to the steady state C.sub.max achieved after three days of PO BID dosing of 120 mg sotalol hydrochloride) in a subject dosed with 80 mg of oral sotalol hydrochloride between about 12 hours and about 24 hours before the intravenous administration. In some embodiments, the sotalol hydrochloride can be administered to the subject at a rate between about 0.825 mg/min and about 1.17 mg/min over a period of about 60 minutes.

(45) In some embodiments, during administration of between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride over a period of about 60 minutes, intravenous administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 to 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In a particular embodiment, during administration of between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride over a period of about 60 minutes, intravenous administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In another embodiment, during administration of between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride over a period of about 60 minutes, intravenous administration is discontinued or reduced when the subject has a QTc interval that is greater than 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(46) Alternatively, and in other embodiments, 120 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours after the completion of the intravenous administration of about 55 mg to about 64 mg of sotalol hydrochloride. In some embodiments, 120 mg of sotalol hydrochloride is administered orally between about 2 hours and about 6 hours, between about 2 and about 5 hours, between about 2 and about 4 hours, between about 2 hours and about 3 hours, between about 3 hours and about 6 hours, between about 3 hours and about 5 hours, between about 3 hours and about 4 hours, between about 4 hours and about 6 hours, between about 4 hours and about 5 hours, or between about 5 hours and about 6 hours after the completion of the intravenous administration of about 55 mg to about 64 mg of sotalol hydrochloride.

(47) In some embodiments, oral administration is discontinued or reduced when the subject has a

QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to the oral administration of sotalol hydrochloride. In a particular embodiment, oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to the oral administration of sotalol hydrochloride. In another embodiment, oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to the oral administration of sotalol hydrochloride.

(48) In other embodiments, BID PO administration of 120 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of 120 mg of sotalol hydrochloride that is less than or equal to 480 msec to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In a particular embodiment, BID PO administration of 120 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of 120 mg of sotalol hydrochloride that is less than or equal to 480 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In another embodiment, BID PO administration of 120 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of 120 mg of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration.

(49) Subjects with impaired renal function safely transitioned to the higher dose can take 120 mg sotalol once daily as discussed elsewhere herein.

(50) Dose Escalation from 120 mg to 160 mg Oral Sotalol Hydrochloride

(51) In some embodiments, about 63 to about 88 mg of sotalol hydrochloride can be administered intravenously over about 60 minutes to provide an average sotalol steady state C<sub>sub</sub>.max of about 1600 ng/mL. In a particular embodiment, about 70 mg to about 80 mg of sotalol hydrochloride can be safely administered intravenously over a period of about 60 minutes to provide an average sotalol steady state C<sub>sub</sub>.max of about 1600 ng/mL (corresponding to the steady state C<sub>sub</sub>.max achieved after three days of PO BID dosing of 160 mg sotalol hydrochloride) in a subject dosed with 120 mg of oral sotalol hydrochloride between about 12 hours and about 24 hours before the intravenous administration. In some embodiments, the sotalol hydrochloride can be administered to the subject at a rate between about 1.05 mg/min and about 1.47 mg/min over a period of about 60 minutes.

(52) In some embodiments, during administration of between about 1.05 mg/min and about 1.47 mg/min of sotalol hydrochloride over a period of about 60 minutes, intravenous administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 to 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In one embodiment, during administration of between about 1.05 mg/min and about 1.47 mg/min of sotalol hydrochloride over a period of about 60 minutes, intravenous administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In another embodiment, during administration of between about 1.05 mg/min and about 1.47 mg/min of sotalol hydrochloride over a period of about 60 minutes, intravenous administration is discontinued or reduced when the subject has a QTc interval that is greater than 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(53) Alternatively, and in other embodiments, 160 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours after the completion of the intravenous



administration of about 70 mg to about 80 mg of sotalol hydrochloride. In some embodiments, 160 mg of sotalol hydrochloride can be administered orally between about 2 hours and about 6 hours, between about 2 hours and about 5 hours, between about 2 hours and about 4 hours, between about 2 hours and about 3 hours, between about 3 hours and about 6 hours, between about 3 hours and about 5 hours, between about 3 hours and about 4 hours, between about 4 hours and about 6 hours, between about 4 hours and about 5 hours, or between about 5 hours and about 6 hours after the completion of the intravenous administration of about 70 mg to about 80 mg of sotalol hydrochloride.

(54) In some embodiments, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec to 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In one embodiment, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 480 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In another embodiment, further oral administration is discontinued or reduced when the subject has a QTc interval that is greater than 500 msec; or when the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(55) In other embodiments, BID PO administration of 160 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 480 msec to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In some embodiments, BID PO administration of 160 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 480 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration. In other embodiments, BID PO administration of 160 mg of sotalol hydrochloride can be initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after initial oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or when the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to sotalol administration.

(56) Subjects with impaired renal function safely transitioned to the higher dose can take 160 mg sotalol once daily as discussed elsewhere herein.

(57) Method of Reducing Hospital Stay

(58) In some embodiments, the disclosure provides a method of reducing a hospital stay in a subject in need of treatment or prevention of atrial fibrillation, atrial flutter, or a combination thereof, the method comprising introducing a subject to sotalol hydrochloride administered intravenously over a period of about 60 minutes in the absence of further sotalol administration for a period of about 2 hours to about 6 hours after the period of about 60 minutes.

(59) In some embodiments, about 0.825 mg/min to about 1.17 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period. In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 750 ng/mL and about 850 ng/mL in the subject.

(60) In some embodiments, about 1.23 mg/min to about 1.76 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period. In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1150 ng/mL and about 1250 ng/mL in the subject.

(61) In some embodiments, about 1.65 mg/min to about 2.35 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period. In some embodiments, the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1550 ng/mL and about 1650 ng/mL in the subject.

(62) In some embodiments, where the subject received 80 mg oral sotalol hydrochloride about 12 hours to about 24 hours before the intravenous administration, about 0.825 mg/min to about 1.17 mg/min of sotalol hydrochloride can be intravenously administered over the about 60 minute period to safely escalate sotalol hydrochloride dosing to 120 mg oral sotalol hydrochloride.

(63) In yet another embodiment, where the subject received 120 mg oral sotalol hydrochloride about 12 hours to about 24 hours before the intravenous administration, between about 1.05 mg/min and about 1.47 mg/min of sotalol hydrochloride can be intravenously administered over the about 60 minute period to safely escalate sotalol hydrochloride dosing to 160 mg oral sotalol hydrochloride.

(64) In any of the embodiments described above, the intravenous administration of sotalol hydrochloride can be discontinued or reduced when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 480 msec to 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration. In any of the embodiments described above, the intravenous administration of sotalol hydrochloride can be discontinued or reduced when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 480 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

Alternatively, in any of the embodiments described above, the intravenous administration of sotalol hydrochloride can be discontinued or reduced when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(65) In some embodiments, sotalol hydrochloride is orally administered between about 2 hours and about 6 hours after completion of the intravenous administration.

(66) In some embodiments, 80 mg of sotalol hydrochloride can be orally administered between about 2 and about 6 hours after completing intravenous administration of about 0.825 mg/min to about 1.17 mg/min of sotalol hydrochloride.

(67) In some embodiments, 120 mg of sotalol hydrochloride can be orally administered between about 2 hours and about 6 hours after completing intravenous administration of about 1.23 mg/min to about 1.76 mg/min of sotalol hydrochloride.

(68) In some embodiments, 160 mg of sotalol hydrochloride can be orally administered between about 2 hours and about 6 hours after completing intravenous administration of about 1.65 mg/min to about 2.35 mg/min of sotalol hydrochloride.

(69) In some embodiments, the oral administration of sotalol hydrochloride is discontinued or reduced when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration. In a particular embodiment, the oral administration of sotalol hydrochloride is discontinued or reduced when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is greater than 480 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration. In another particular embodiment, the oral administration of sotalol hydrochloride is discontinued or reduced when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(70) As described elsewhere herein, when a subject has a QTc interval that is acceptable and/or wherein the subject has a  $\Delta$ QTc that is less than or equal to 20% of the subject's QTc prior to intravenous sotalol administration, the subject can be transitioned to BID PO dosing, or QD (once daily) PO dosing, as appropriate for the subject's renal function.

Embodiments

(71) In addition to the various embodiments described above, the present disclosure includes the following specific embodiments numbered E1 through E27. This list of embodiments is presented as an exemplary list and the application is not limited to these embodiments.

(72) E1. A method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride over a period of about 60 minutes.

(73) E2. The method of E1, further comprising discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(74) E3. The method of E1, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 750 ng/mL and about 850 ng/mL in the subject.

(75) E4. The method of E3, further comprising orally administering to the subject 80 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(76) E5. The method of E4, further comprising discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(77) E6. The method of E4, further comprising initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to intravenous sotalol administration.

(78) E7. A method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 1.23 mg/min and about 1.76 mg/min of sotalol hydrochloride over a period of about 60 minutes.

(79) E8. The method of E7, further comprising discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(80) E9. The method of E7, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1150 ng/mL and about 1250 ng/mL in the subject.

(81) E10. The method of E9, further comprising orally administering to the subject 120 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(82) E11. The method of E10, further comprising discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(83) E12. The method of E10, further comprising initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to intravenous

sotalol administration.

(84) E13. A method of treating atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 1.65 mg/min and about 2.35 mg/min of sotalol hydrochloride over a period of about 60 minutes.

(85) E14. The method of E13, further comprising discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(86) E15. The method of E13, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1550 ng/mL and about 1650 ng/mL in the subject.

(87) E16. The method of E15, further comprising orally administering to the subject 160 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(88) E17. The method of E16, further comprising discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(89) E18. The method of E16, further comprising initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% the subject's QTc prior to intravenous sotalol administration.

(90) E19. A method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride over a period of about 60 minutes, wherein the subject received an administration of sotalol hydrochloride between about 12 hours and about 24 hours before the intravenous administration.

(91) E20. The method of E19, wherein the subject received an oral administration of 80 mg of oral sotalol hydrochloride between about 12 and about 24 hours before the intravenous administration.

(92) E21. The method of E19, further comprising discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(93) E22. The method of E19, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1150 ng/mL and about 1250 ng/mL in the subject.

(94) E23. The method of E22, further comprising orally administering to the subject 120 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(95) E24. The method of E23, further comprising discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(96) E25. The method of E23, further comprising initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% the subject's QTc prior to intravenous sotalol

administration.

(97) E26. A method of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof in a subject in need thereof, the method comprising intravenously administering to the subject between about 1.05 mg/min and about 1.47 mg/min of sotalol hydrochloride over a period of about 60 minutes, wherein the subject received an administration of sotalol hydrochloride between about 12 hours and about 24 hours before the intravenous administration.

(98) E27. The method of E26, wherein the subject received an oral administration of 120 mg of oral sotalol hydrochloride between about 12 and about 24 hours before the intravenous administration.

(99) E28. The method of E26, further comprising discontinuing or reducing intravenous administration of sotalol hydrochloride when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.

(100) E29. The method of E26, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1550 ng/mL and about 1650 ng/mL in the subject.

(101) E30. The method of E29, further comprising orally administering to the subject 160 mg of sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.

(102) E31. The method of E30, further comprising discontinuing or reducing oral administration of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and about 5 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.

(103) E32. The method of E30, further comprising initiating an oral BID administration regimen of sotalol hydrochloride when the subject has a QTc interval at between about 2 hours and 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% the subject's QTc prior to intravenous sotalol administration.

(104) E33. A method of reducing a hospital stay of a subject in need of treatment or prevention of atrial fibrillation, atrial flutter, or a combination thereof, the method comprising stabilizing a subject on sotalol hydrochloride administered intravenously over a period of about 60 minutes in the absence of further sotalol administration for a period of about 2 hours to about 6 hours after the period of about 60 minutes.

(105) E34. The method of E33, wherein the hospital stay is reduced to between about 18 hours and about 24 hours.

(106) E35. The method of E33, wherein the hospital stay is reduced to between about 20 hours and about 24 hours.

(107) E36. The method of E33, wherein between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period.

(108) E37. The method of E33, wherein between about 1.23 mg/min and about 1.76 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period.

(109) E38. The method of E33, wherein between about 1.65 mg/min and about 2.35 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period.

(110) E39. The method of E33, wherein the subject received oral sotalol hydrochloride between about 12 hours and about 24 hours before the intravenous administration.

(111) E40. The method of E39, wherein between about 0.825 mg/min about 1.17 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period.

(112) E41. The method of E39, wherein between about 1.05 mg/min and about 1.47 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period.

- (113) E42. The method of E33, wherein the intravenous administration of sotalol hydrochloride is discontinued or reduced when the subject has a QTc interval after intravenous sotalol hydrochloride initiation that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to sotalol administration.
- (114) E43. The method of E36, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 750 ng/mL and about 850 ng/mL in the subject.
- (115) E44. The method of E37, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1150 ng/mL and about 1250 ng/mL in the subject.
- (116) E45. The method of E38, wherein the intravenous administration of sotalol hydrochloride results in a sotalol steady state C.sub.max of between about 1550 ng/mL and about 1650 ng/mL in the subject.
- (117) E46. The method E33, further comprising orally administering to the subject sotalol hydrochloride between about 2 hours and about 6 hours after completion of the intravenous administration.
- (118) E47. The method of E33, wherein 80 mg of sotalol hydrochloride is orally administered between about 5 and about 8 hours after completion of intravenous administration of between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride.
- (119) E48. The method of E33, wherein 120 mg of sotalol hydrochloride is orally administered between about 2 hours and about 6 hours after completion of intravenous administration of between about 1.23 mg/min and about 1.76 mg/min of sotalol hydrochloride.
- (120) E49. The method of E33, wherein 160 mg of sotalol hydrochloride is orally administered between about 2 hours and about 6 hours after completion of intravenous administration of between about 1.65 mg/min and about 2.35 mg/min of sotalol hydrochloride.
- (121) E50. The method of E46, wherein the oral administration of sotalol hydrochloride is discontinued or reduced when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is greater than 500 msec; or wherein the subject has a  $\Delta$ QTc that is greater than or equal to 20% of the subject's QTc prior to intravenous sotalol administration.
- (122) E51. The method of E46, wherein an oral administration BID regimen of sotalol hydrochloride is initiated when the subject has a QTc interval at between about 2 hours and about 3 hours after oral administration of sotalol hydrochloride that is less than or equal to 500 msec; or wherein the subject has a  $\Delta$ QTc that is less than 20% of the subject's QTc prior to intravenous sotalol administration.
- (123) E52. A method of administering sotalol hydrochloride to a subject in need thereof, the method comprising intravenously administering sotalol hydrochloride over a period of about 60 minutes to reach a sotalol steady state C.sub.max in the subject, wherein the subject has a QTc interval during the intravenous administration of sotalol hydrochloride that is less than or equal to 500 msec; and wherein the subject has a  $\Delta$ QTc during sotalol hydrochloride administration that is less than 20% of the subject's QTc prior to intravenous sotalol administration.
- (124) E53. The method of E52, wherein the sotalol steady state C.sub.max is between about 750 ng/mL and about 850 ng/mL.
- (125) E54. The method of E52, wherein the steady sotalol state C.sub.max is between about 1150 ng/mL and about 1250 ng/mL.
- (126) E55. The method of E52, wherein the steady sotalol state C.sub.max is between about 1550 ng/mL and about 1650 ng/mL.
- (127) E56. The method of E52, wherein between about 0.825 mg/min and about 1.17 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period.
- (128) E57. The method of E52, wherein between about 1.23 mg/min and about 1.76 mg/min of

sotalol hydrochloride is intravenously administered over the about 60 minute period.

(129) E58. The method of E52, wherein between about 1.65 mg/min and about 2.35 mg/min of sotalol hydrochloride is intravenously administered over the about 60 minute period.

(130) E59. A method to administer a loading dose of Sotalol entirely intravenously to a target maximum serum concentration that a subject is expected to be exposed in the course of chronic oral dosing of Sotalol.

(131) E60. A method to administer sotalol intravenously to a target concentration in order to see the maximum QTc interval increment that can be expected to be expressed by a subject in the course of chronic oral therapy, while maximizing subject safety during initial loading process.

(132) E61. A method permitting the targeting of the projected maximum concentration of sotalol hydrochloride that may be attained on chronic dosing in a period of one hour, permitting the adjustment of the dosing, or its cessation for subject safety dependent on QTc interval prolongation.

(133) E62. A way to initiate sotalol hydrochloride therapy in a subject with an indication to receive chronic sotalol therapy employing an intravenous infusion.

(134) E63. The use of an intravenous infusion to obtain sotalol hydrochloride steady state C.sub.max concentration to the level obtained with chronic oral sotalol hydrochloride dosing.

(135) E64. A way to obtain steady state C.sub.max to observe changes in cardiac repolarization such that the increase in QTc is not greater than specified in guidelines and thus, not risking the development of life threatening ventricular arrhythmias.

(136) E65. A method of administering sotalol hydrochloride, observing the changes in QTc such that if the QTc increases beyond acceptable parameters, the infusion can be terminated immediately, enhancing subject safety.

(137) E66. A method of increasing sotalol hydrochloride dose from low dose oral therapy to higher dose oral therapy using an intravenous infusion.

(138) E67. A method of dose escalation of sotalol hydrochloride such that the infusion obtains the projected steady state C.sub.max and thus maximum QTc changes in a brief period of time, avoiding changes in QTc in excess of those expected to be experienced by a subject receiving an appropriate dose of sotalol and thus reducing the risk of drug induced arrhythmias.

(139) E68. A method of dose initiation and dose escalation employing intravenous sotalol hydrochloride in subjects with renal dysfunction. Providing the attainment of steady state C.sub.max and thus, the full exposure of QTc changes under electrocardiographic observation within 24 hours of exposure.

## EXAMPLES

(140) The following examples are illustrative and non-limiting, of the methods described herein. Suitable modifications and adaptations of the variety of conditions, formulations, and other parameters normally encountered in the field and which are obvious to those skilled in the art in view of this disclosure are within the spirit and scope of the invention.

### Example 1: IV Sotalol

(141) A subject with a QTc interval of 405 msec is to receive 80 mg of oral sotalol hydrochloride by mouth twice a day (PO BID) with a steady state serum concentration reached in 3-5 days with a steady state C.sub.max of 800 ng/mL. With the relationship of QTc to serum concentration on average of 0.024:

$$\begin{aligned} \text{QTc}_{\text{max}} &= \text{QTc}_{\text{baseline}} + (0.024 \times 800 \text{ ng/mL}) \\ (142) \quad &= 424 \text{ msec}^* \end{aligned}$$

\*Within the prescribed FDA guideline of remaining under a maximum QTc of 500 msec.

(143) Dose Initiation: To attenuate the time required to achieve steady state C<sub>max</sub>, one can administer sotalol hydrochloride IV as an infusion. For example, 55 mg (projected to equate to 80 mg by mouth twice a day) of IV sotalol hydrochloride can be administered over 1-2 hours, the steady state C.sub.max estimated for an average person's serum sotalol concentration 800 ng/mL

would be achieved, which would transpose to a QTc prolongation of an average of 427 msec.

#### Example 2: IV Sotalol

(144) A subject with an initial QTc of 405 msec (average for a 70 kg person) starts receiving a sotalol hydrochloride IV infusion of 55 mg/mL and after 45 minutes the QTc is measured to be 456 msec. The infusion can be halted and the dose of sotalol hydrochloride selected for chronic administration can be reduced, the dosing interval can be prolonged, or the physician can decide not to use sotalol hydrochloride and instead turn to an alternative anti-arrhythmic therapy.

(145) IV loading could safely expose the subject to the expected maximum sotalol hydrochloride concentration and thus maximum QTc prolongation that would be expected to occur with chronic dosing. If under observation, the QTc prolongs to a significantly greater degree, the infusion can be stopped, the dose reduced, or the subject deemed too sensitive to sotalol hydrochloride dosing and another antiarrhythmic drug could be evaluated for efficacy and safety in that particular subject. This approach would be a major safety factor for subjects, since with oral loading or oral and IV loading, the absorption continues once a pill is taken and the overshoot in QTc will continue, placing the subject at greater risk. An infusion thus provides greater safety, since the infusion can be stopped with no further significant increase in QTc.

#### Example 3: IV Sotalol

(146) A 70 kg subject presents with intermittent atrial fibrillation (AF). His physician wants to place the subject on oral sotalol hydrochloride 80 mg PO BID. He has never taken sotalol before. He is admitted to the hospital and receives an infusion of IV sotalol hydrochloride (55 mg) over 1 hour. This infusion achieves a target serum concentration of 800 ng/mL. Following the infusion the QTc is checked 30 minutes after administration. If the QTc is within guidelines (less than 20% increase, or under 500 msec) an interval of 2-6 hours is left to elapse to reach the predicted trough and then 80 mg orally is given to subject, which will predictably peak in 2-4 hours and QTc will be measured again hourly (at 4-5 hours). If QTc is within guidelines, then dosing will continue orally, 80 mg every 12 hours.

(147) The subject will thus have been exposed to a serum sotalol hydrochloride concentration predicted to be reached with chronic dosing (predicted C<sub>sub</sub>.max) twice in the 16 hours of observation and can be discharged safely in 24 hours knowing that the QTc will not at maximum predicted concentration exceed guidelines. Thus, in a timeframe of between 6-23 hours, sotalol hydrochloride could be fully evaluated for repolarization safety with the maximum QTc expected at a given chronic dose.

(148) That some subjects respond unpredictably to sotalol hydrochloride, or other QT prolonging drugs is well-known. This can be explained in the case of sotalol hydrochloride by an abnormality in the potassium channel. Genetic conditions can cause mild abnormalities in protein structure of the potassium channel. These abnormalities can be dormant and only seen as marked QT prolongation when subjects are exposed to a potassium channel blocker such as sotalol hydrochloride. In these subjects with a channelopathy, the QTc may markedly increase with ensuing life threatening ventricular arrhythmias and possibly sudden cardiac death. Having a way to rapidly access the QTc effect of sotalol hydrochloride by administering an intravenous infusion when the drug administration could be halted at any time will greatly enhance subject safety. As can be seen in FIG. 1, the exposure to sotalol through an IV infusion over several hours can achieve steady state C<sub>max</sub> and the maximum QTc in a short period of time (less than 24 hours). Thus, permitting evaluation in hospital over 24 hours as opposed to the 3 day hospitalization currently needed to achieve steady state C<sub>sub</sub>.max levels with oral sotalol hydrochloride dosing.

(149) Another critical factor in the dosing of sotalol hydrochloride to observe maximum QTc effect is the relation of the serum concentration and QTc prolongation based on time. The phenomenon is called hysteresis: the delay between a change in a marker affected by an exposure to an agent causing its change. This can be due to delay of the drug reaching the receptor or channel or changes in the receptor or channel needed over time to be fully expressed. Information on sotalol



concentration and QTc prolongation is known from the work of Somberg and colleagues. In Somberg, J. C., et al., *Am. J. Ther.* 17(4):365-72 (2010) 15 normal individuals received sotalol hydrochloride infused intravenously and then at a later date administered orally. The infusion was over a 2.5 hour duration and thus the serum concentration would be at a maximum at the end of infusion (2.5 hours). The maximum QTc was seen at 2.25 hours. Thirty minutes later at hour 3, the QTc had decreased. Thus, the hysteresis between sotalol hydrochloride concentration and QTc cannot be longer than 30 minutes. Therefore, a period of 30 minutes is recommended to observe the maximum QTc effect after the completion of the infusion, to observe and then act upon the maximum QTc observed.

#### (150) Dose Escalation

(151) In an analogous manner a subject on a maintenance dose of 80 mg PO BID sotalol hydrochloride, or 120 mg PO BID could be increased to the next standard increment in oral dosing. A subject could be brought in to the hospital at the time before the next dosing interval, nadir of serum concentration, and administered an infusion over 1-2 hours of IV sotalol hydrochloride to attain the projected next highest concentration level (steady state C.sub.max) and thus the maximum concentration the subject would be exposed to, resulting in the maximum QTc predicted exposure. This could be done in hospital in less than 24 hours such that the full risk to the subject of that serum sotalol hydrochloride concentration could be observed as shown in FIG. 2. If arrhythmias occur, cardiac resuscitation measures could be initiated, offering the subject maximal safety. If the infusion is given intravenously, the infusion could be terminated if the QTc increases beyond acceptable parameters recommended by FDA in the sotalol hydrochloride product label.

#### Example 4: IV Sotalol

(152) A subject on 80 mg PO BID is brought to hospital at end of dosing interval before the next oral dose and then, receives an IV infusion of sotalol hydrochloride. Trough concentration of sotalol hydrochloride given at 80 mg PO BID can be estimated to be 400 ng/mL. The steady state C.sub.max of a 120 mg PO BID dose would be 1200 ng/mL. Thus, an infusion of 55 mg sotalol hydrochloride would achieve a target concentration of approximately 1200 ng/mL, exposing the subject to the maximal predicted QTc prolongation in 2 hours or less. In both the initiating and loading periods one may then proceed to continue oral dosing after a preset interval (2-6 hours) to continue sotalol hydrochloride exposure to provide anti-arrhythmic action during the transition from IV to oral drug administration.

(153) While the methods have been described in terms of what are presently considered to be practical and preferred embodiments, it is to be understood that the disclosure need not be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar embodiments. This disclosure includes any and all embodiments of the following claims.

(154) Having now fully described this invention, it will be understood by those of ordinary skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any embodiment thereof. All patents, patent applications, and publications cited herein are fully incorporated by reference herein in their entirety.

## Claims

1. A method of rapidly escalating a subject's oral sotalol hydrochloride therapy to a higher oral dose, the method comprising: (1) identifying a subject as having symptomatic atrial fibrillation or atrial flutter, who is currently in sinus rhythm, who is under QTc monitoring, and who is receiving 120 mg oral sotalol hydrochloride therapy such that the subject has a concentration of sotalol resulting therefrom; (2) escalating the concentration of sotalol of the subject to a higher

- concentration, by administering over a period of 1 hour, a single IV dosage of sotalol hydrochloride in an amount in the range of 99 mg to 105.6 mg and at a rate in the range of 1.65-1.76 mg/min; and (3) after completion of the single IV dosage of sotalol hydrochloride, increasing the amount of the subject's oral dosing from 120 mg to 160 mg by administering at least one oral dose of 160 mg sotalol hydrochloride to the subject.
2. The method of claim 1, further comprising repeating oral administration of the 160 mg oral dose of sotalol hydrochloride at least once at a selected interval.
  3. The method of claim 2, wherein the administering of the oral dose of 160 mg starts at about 4-12 hours after completion of the single IV dosage of sotalol hydrochloride.
  4. The method of claim 3, wherein the administering of the oral dose of 160 mg starts at about 4 hours after completion of the single IV dosage of sotalol hydrochloride.
  5. The method of claim 1, wherein: the administering of the oral dose of 160 mg starts at about 6 hours after completion of the single IV dosage of sotalol hydrochloride.
  6. The method of claim 5, further comprising repeating oral administration of the 160 mg oral dose of sotalol hydrochloride at a selected interval, wherein the repeating of the oral administration is performed at least once.
  7. The method of claim 1, wherein: the administering of the oral dose of 160 mg starts at about 4-12 hours after completion of the single IV dosage of sotalol.
  8. The method of claim 7, further comprising repeating oral administration of the 160 mg oral dose of sotalol hydrochloride at a selected interval, wherein the administering of the oral dose of 160 mg and the repeating of the oral administration is performed at least once and according to a once daily or twice daily schedule.
  9. The method of claim 1, wherein the subject received a 120 mg oral dose of sotalol hydrochloride 12-24 hours before administration of the single IV dose.
  10. The method of claim 2, wherein the administering of the oral dose of 160 mg and the repeating is performed according to a once or twice daily schedule.
  11. The method of claim 3, wherein the administering of the oral dose of 160 mg and the repeating is performed according to a once or twice daily schedule.
-